Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-05-31FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for LAMICTAL ODT (lamotrigine) submitted by GlaxoSmithKline LLC.
-
CLINICAL_TRIALS trial_result · 2011-05-26Clinical Trial Update: Olanzapine Treatment of Patients With Bipolar I Disorder [Phase 3]
Phase 3 clinical trial evaluating olanzapine for bipolar I disorder has completed, with results posted in 2011.
-
FDA approval · 2011-05-25FDA Approved: RISPERIDONE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved the original application for risperidone generic manufactured by Amneal Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2011-05-24Clinical Trial Update: Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients [Phase 3]
A Phase 3 trial comparing cognitive/sedative effects of risperidone vs. quetiapine in stable Bipolar I outpatients has completed.
-
CLINICAL_TRIALS trial_result · 2011-05-24Clinical Trial Update: Naltrexone for Bipolar Disorder and Alcohol Dependence [Phase 4]
A Phase 4 clinical trial evaluating naltrexone for bipolar disorder and alcohol dependence has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2011-05-20FDA Approved: CARBAMAZEPINE — Original Application (ANI Pharmaceuticals, Inc.)
FDA approves ANI Pharmaceuticals' original application to market a generic carbamazepine formulation under an ANDA.
-
CLINICAL_TRIALS trial_result · 2011-05-19Clinical Trial Update: Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting [Phase 3]
This update covers a Phase 3 trial comparing topiramate added to placebo for outpatients with bipolar disorder, which has completed.
-
CLINICAL_TRIALS trial_result · 2011-05-19Clinical Trial Update: A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes. [Phase 3]
Phase 3 trial assessed the effectiveness and safety of Risperdal CONSTA added to standard treatment in bipolar disorder patients who have fr…
-
CLINICAL_TRIALS research · 2011-05-19Clinical Trial Update: ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry
Completed clinical trial registry entry for the ADH.E.R.E. mental health registry sponsored by Janssen-Cilag S.A., evaluating therapeutic ad…
-
CLINICAL_TRIALS trial_result · 2011-05-18Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder [Phase 3]
Phase 3 trial evaluating adjustable doses of extended-release paliperidone, in combination with lithium or valproate, versus placebo for man…
-
CLINICAL_TRIALS trial_result · 2011-05-18Clinical Trial Update: A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder [Phase 3]
A Phase 3 trial evaluating the safety and efficacy of topiramate in patients with bipolar disorder has completed.
-
CLINICAL_TRIALS trial_result · 2011-05-18Clinical Trial Update: A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder [Phase 1]
Phase 1 study evaluating how carbamazepine affects the pharmacokinetics of paliperidone extended-release in people with schizophrenia or bip…
-
FDA approval · 2011-05-18FDA Approved: RISPERIDONE — Original Application (Chartwell RX, LLC)
FDA approves Chartwell RX, LLC's original application for a generic risperidone product (ANDA 077543). The approval enables marketing of the…
-
FDA approval · 2011-05-17FDA Approved: SEROQUEL XR — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for SEROQUEL XR (quetiapine) by AstraZeneca Pharmaceuticals LP to update or expand the labeling.
-
CLINICAL_TRIALS trial_result · 2011-05-02Clinical Trial Update: A Study of Transcranial Direct Current Stimulation (tDCS) to Treat Depression [Phase 2, Phase 3]
The study of transcranial direct current stimulation (tDCS) for treating depression completed Phase 2 and Phase 3 trials.
-
CLINICAL_TRIALS trial_result · 2011-04-27Clinical Trial Update: A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania [Phase 4]
Phase 4 trial update of aripiprazole (Abilify) in bipolar mania; results posted in 2011.
-
FDA approval · 2011-04-25FDA Approved: LAMICTAL XR — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for Lamictal XR (lamotrigine) by GlaxoSmithKline LLC.
-
FDA approval · 2011-04-19FDA Approved: RISPERIDONE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for risperidone from Aurobindo Pharma Limited, marking clearance to market this generic product.
-
FDA approval · 2011-04-05FDA Approved: DIVALPROEX SODIUM — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved the generic divalproex sodium from Unichem Pharmaceuticals (USA), Inc. under ANDA079163.
-
FDA approval · 2011-03-30FDA Approved: LAMOTRIGINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Lamotrigine from Aurobindo Pharma Limited. This approval confirms the availability of the lamotr…
-
FDA approval · 2011-03-30FDA Approved: RISPERIDONE — Original Application (Natco Pharma USA LLC)
FDA approved Natco Pharma USA LLC's original ANDA for risperidone, enabling a generic version of the antipsychotic. The approval allows Natc…
-
CLINICAL_TRIALS trial_result · 2011-03-29Clinical Trial Update: European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes
This completed European clinical trial describes hospital stay and related outcomes for patients admitted with acute bipolar manic episodes.
-
FDA approval · 2011-03-16FDA Approved: RISPERIDONE — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
FDA approved a supplemental application for risperidone from Jubilant Cadista Pharmaceuticals Inc., confirming continued approval of the gen…
-
FDA approval · 2011-03-03FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tegretol (carbamazepine) from Novartis Pharmaceuticals Corporation, authorizing changes to the p…
-
FDA approval · 2011-03-02FDA Approved: ABILIFY — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
FDA approved a supplemental NDA for ABILIFY (aripiprazole) submitted by Otsuka America Pharmaceutical, Inc., to modify the product labeling …